Tocilizumab for cystoid macular edema secondary to retinitis pigmentosa
IV TCZ can be an effective treatment option in RP-related CME and RVL. Whether this treatment strategy has an effect on prognosis remains to be established, but it is possible considering chronic CME-related retinal damage is a major driver of central vision loss in RP.
Authors
- Isabelle Nubourgh
- Stéphane Abramowicz (ORCID: https://orcid.org/0000-0002-4450-3211)
- Laurence Dominique Postelmans (ORCID: https://orcid.org/0000-0001-5333-3077)
- Prochore Kamgang Semeu (ORCID: https://orcid.org/0000-0002-2567-2431)
- François Willermain
Institutions
- Université Libre de Bruxelles (BE)
- Centre Hospitalier Universitaire Brugmann (BE)
- Centre Hospitalier Universitaire de Saint-Pierre (BE)
Publication Details
- Journal
- Journal of Ophthalmic Inflammation and Infection
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1186/s12348-024-00430-0
- Citations
- 1
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.54